This invention relates to (E)-.alpha.-[2-n-butyl-1-[(4-carboxyphenyl)methyl)-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid arginyl charge-neutralization-complex, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.
EPROSARTAN ARGINYL CHARGE-NEUTRALIZATION-COMPLEX AND A PROCESS FOR ITS PRODUCTION AND FORMULATION